Suppr超能文献

α-肾上腺素能受体亚型

Alpha-adrenoceptor subtypes.

作者信息

Civantos Calzada B, Aleixandre de Artiñano A

机构信息

Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid, Spain.

出版信息

Pharmacol Res. 2001 Sep;44(3):195-208. doi: 10.1006/phrs.2001.0857.

Abstract

Different studies have led to our present knowledge of the membrane receptors responsible for mediating the responses to the endogenous catecholamines. These receptors were initially differentiated into alpha - and beta-adrenoceptors. Alpha-adrenoceptors mediate most excitatory functions, and were in turn differentiated in the 1970s into alpha(1)- and alpha(2)-adrenoceptors. The alpha(1)-adrenoceptor type usually mediates responses in the effector organ. The alpha(2)-adrenoceptor type is located presynaptically and regulates the release of the neurotransmitter but it is also present in postsynaptical locations. Both alpha-adrenoceptors are important for the control of vascular tone, but we now know that neither alpha(1)- nor alpha(2)-adrenoceptors constitute homogeneous groups. Each alpha-adrenoceptor type can be subdivided into different subtypes and in this review we have turned our attention to these. The alpha(1)- and the alpha(2)-adrenoceptor subtypes were previously defined pharmacologically by functional and binding studies, and later they were also isolated and identified using cloning methods. In fact, the study of alpha-adrenoceptors was revolutionized by the techniques of molecular biology which permitted us to establish the present classification. The present classification of alpha(1)-adrenoceptors stands as follows: alpha(1A)-adrenoceptor subtype (cloned alpha(1c) and redesignated alpha(1a/c)), alpha(1B)-adrenoceptor subtype (cloned alpha(1b)) and alpha(1D)-adrenoceptor subtype (cloned alpha(1d) and redesignated alpha(1a/d)). It has not been easy to establish the distribution of these alpha(1)-adrenoceptor subtypes in the various organs and tissues, or to define the functional response mediated by each one in the different species studied. Nevertheless it seems that the alpha(1A)-adrenoceptor subtype is more implicated in the maintenance of vascular basal tone and of arterial blood pressure in conscious animals, and the alpha(1B)-adrenoceptor subtype participates more in responses to exogenous agonists. It has also been observed that the expression of the alpha(1B)-adrenoceptor subtype can be modified in pathological situations and particular attention has been paid to the regulation of expression of this receptor. The present classification of alpha(2)-adrenoceptors stands as follows: alpha(2A/D)-adrenoceptor subtype (today it is accepted that the alpha(2A)-adrenoceptor subtype and the alpha(2D)-adrenoceptor subtype are the same receptor but they were identified in different species: the alpha(2A) in human and the alpha(2D) in rat); alpha(2B)-adrenoceptor subtype (cloned alpha(2b)) and alpha(2C)-adrenoceptor subtype (cloned alpha(2c)). Today we know that the alpha(2A/D)- and alpha(2B)-adrenoceptor subtypes in particular control arterial contraction, and that the alpha(2C)-adrenoceptor subtype is responsible above all for venous vasoconstriction. We also know that the alpha(2 A/D)-adrenoceptor subtype fundamentally mediates the central effects of the alpha(2)-adrenoceptor agonists. Despite the validity of the above-mentioned classification of the alpha(1)- and alpha(2)-adrenoceptors, it seems clear that the contractions of a large number of tissues including smooth muscle are mediated by more than one alpha-adrenoceptor subtype. Moreover, few ligands recognise only one alpha-adrenoceptor subtype and the lack of specifity in the different drugs for each one limits their administration in vivo and their therapeutic use.

摘要

不同的研究使我们对介导对内源性儿茶酚胺反应的膜受体有了目前的认识。这些受体最初被区分为α-和β-肾上腺素能受体。α-肾上腺素能受体介导大多数兴奋性功能,并且在20世纪70年代又被进一步区分为α(1)-和α(2)-肾上腺素能受体。α(1)-肾上腺素能受体类型通常介导效应器器官中的反应。α(2)-肾上腺素能受体类型位于突触前,调节神经递质的释放,但它也存在于突触后位置。两种α-肾上腺素能受体对血管张力的控制都很重要,但我们现在知道α(1)-和α(2)-肾上腺素能受体都不构成同质群体。每种α-肾上腺素能受体类型都可细分为不同的亚型,在本综述中我们将注意力转向了这些亚型。α(1)-和α(2)-肾上腺素能受体亚型以前通过功能和结合研究在药理学上进行定义,后来也通过克隆方法进行分离和鉴定。事实上,分子生物学技术彻底改变了α-肾上腺素能受体的研究,使我们能够建立目前的分类。目前α(1)-肾上腺素能受体的分类如下:α(1A)-肾上腺素能受体亚型(克隆的α(1c)并重新命名为α(1a/c))、α(1B)-肾上腺素能受体亚型(克隆的α(1b))和α(1D)-肾上腺素能受体亚型(克隆的α(1d)并重新命名为α(1a/d))。确定这些α(1)-肾上腺素能受体亚型在各种器官和组织中的分布,或确定在不同研究物种中每种亚型介导的功能反应并非易事。然而,似乎α(1A)-肾上腺素能受体亚型在维持清醒动物的血管基础张力和动脉血压方面作用更大,而α(1B)-肾上腺素能受体亚型更多地参与对外源性激动剂的反应。还观察到α(1B)-肾上腺素能受体亚型的表达在病理情况下可被改变,并且对该受体表达的调节给予了特别关注。目前α(2)-肾上腺素能受体的分类如下:α(2A/D)-肾上腺素能受体亚型(如今人们认为α(2A)-肾上腺素能受体亚型和α(2D)-肾上腺素能受体亚型是同一受体,但它们在不同物种中被鉴定出来:人类中的α(2A)和大鼠中的α(2D));α(2B)-肾上腺素能受体亚型(克隆的α(2b))和α(2C)-肾上腺素能受体亚型(克隆的α(2c))。如今我们知道,特别是α(2A/D)-和α(2B)-肾上腺素能受体亚型控制动脉收缩,而α(2C)-肾上腺素能受体亚型主要负责静脉血管收缩。我们还知道α(2A/D)-肾上腺素能受体亚型从根本上介导α(2)-肾上腺素能受体激动剂的中枢效应。尽管上述α(1)-和α(2)-肾上腺素能受体的分类是有效的,但很明显,包括平滑肌在内大量组织的收缩是由不止一种α-肾上腺素能受体亚型介导的。此外,很少有配体只识别一种α-肾上腺素能受体亚型,并且不同药物对每种亚型缺乏特异性限制了它们在体内的给药及其治疗用途。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验